Back

Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial

1 September 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Post-myocardial infarction management Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Michael Shechter

Chaim Sheba Medical Center, Ramat Gan (Israel)

5 More presentations in this session

Presentation thumbnail
Beta-blockers improved cardiovascular outcome in AMI patients with severe heart failure: a multi-center real-world study
Doctor R. Guo (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Beta-blocker duration and long-term cardiovascular risk after myocardial infarction with reduced ejection fraction
Doctor S. Fang (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
Antithrombotic therapy in patients with takotsubo cardiomyopathy: is heparin associated with lower mortality? - a nationwide cohort analysis
Doctor S. Hijikata (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Proton pump inhibitors in myocardial infarction: safety paradox in Type 1 vs. Type 2---a multicenter retrospective cohort study
Doctor J. Ren (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
Associate Professor M. Cavender (Chapel Hill, US)
Abstract Slides

Access the full session

Session thumbnail
Post-myocardial infarction management

The Event

Event poster

ESC Congress 2025

1 September 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
thumbnail
Congress Presentation
Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
thumbnail
Congress Presentation
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources